Biogen Stock Soars On Promising Data From Late-Stage Alzheimer's Drug Trial
"Today's announcement gives patients and their families hope that lecanemab, if approved, can potentially slow the progression of Alzheimer's disease," said Biogen CEO Michel Vouna…
